Evidence supporting the use of: Ibutamoren
For the body system: Pituitary (anterior)
Synopsis
Source of validity: Scientific
Rating (out of 5): 4
Ibutamoren (MK-677) is a non-peptide growth hormone secretagogue that stimulates the secretion of growth hormone (GH) by mimicking the action of the endogenous hormone ghrelin at the ghrelin receptor (GHSR) in the anterior pituitary and hypothalamus. Several clinical studies have demonstrated that ibutamoren increases circulating levels of GH and insulin-like growth factor 1 (IGF-1) in both healthy adults and those with GH deficiency. Notably, studies published in peer-reviewed journals, such as those by Smith et al. (1997, Journal of Clinical Endocrinology & Metabolism), have shown that daily oral administration of ibutamoren results in sustained, dose-dependent increases in GH and IGF-1, without significant changes in cortisol or prolactin levels. The anterior pituitary is responsible for producing and releasing GH, and ibutamoren’s action directly targets this gland. Evidence also indicates potential benefits in increasing lean body mass and improving bone mineral density, both outcomes associated with increased GH/IGF-1 levels. However, long-term safety and efficacy data are limited, and ibutamoren is not FDA-approved for clinical use outside of research settings. In summary, scientific evidence demonstrates that ibutamoren supports the anterior pituitary by stimulating GH release, with moderate to strong evidence from human trials.
Other ingredients that support Pituitary (anterior)
alfalfaashwagandha
bovine
l-arginine
hypothalamus
Agnuside
D-Aspartic Acid
Other body systems supported by Ibutamoren
BrainGlandular System
Hypothalamus
Muscles
Pituitary
Pituitary (anterior)
Skeletal System (Bones)